Objective: Prevalence estimates for ADHD have been debated for decades. In France, the only available study states the prevalence rate in France ranges from 3.5% to 5.6% of children aged 6 to 12. It also evaluates that 3.48% of children aged 6 to 12 are treated with psychostimulants. The article uses a different method to determine whether these estimates hold true. Method: Estimating ADHD diagnosis and methylphenidate prescription rates can be done by analyzing national health care insurance system's data. We used data from the French Healthcare Insurance as reported by the National Agency for Medicines and Health Products Safety. Results: We claim that an adequate estimate of the ADHD prevalence rate in France fluctuates around 0.3% of children aged 6 to 11. Discussion: Methodological biases in ADHD prevalence studies and factors contributing to the low level of prescription in France need to be assessed. Conclusion: We call for supplementary investigations in health care insurance databases to conduct contradictory studies.

中文翻译：

---

法国的 ADHD 诊断和药物使用估计：使用医疗保险数据的案例。

目标：对 ADHD 的患病率估计已经争论了几十年。在法国，唯一可用的研究表明，法国 6 至 12 岁儿童的患病率为 3.5% 至 5.6%。它还评估了 3.48% 的 6 至 12 岁儿童接受精神兴奋剂治疗。本文使用不同的方法来确定这些估计是否成立。方法：可以通过分析国家医疗保险系统的数据来估计多动症的诊断和哌甲酯的处方率。我们使用了国家药品和健康产品安全局报告的法国医疗保险的数据。结果：我们声称对法国 ADHD 患病率的充分估计在 6 至 11 岁儿童中波动约 0.3%。 讨论：需要评估 ADHD 患病率研究中的方法论偏差以及导致法国处方水平低的因素。结论：我们呼吁在医疗保险数据库中进行补充调查，以进行相互矛盾的研究。